XIPERE (triamcinolone acetonide) by Bausch + Lomb is corticosteroid hormone receptor agonists [moa]. First approved in 2021.
Drug data last refreshed Yesterday
XIPERE is a triamcinolone acetonide suspension administered via intravitreal injection for treatment of diabetic macular edema (DME). It is a corticosteroid hormone receptor agonist that reduces inflammation in the macula caused by diabetes-related fluid accumulation. The product was approved in October 2021 and represents a corticosteroid-based approach to DME management.
XIPERE is in peak commercial phase with 14 years of patent protection remaining, supporting mid-sized marketing and sales teams focused on ophthalmology specialists.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Worked on XIPERE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moXIPERE careers are concentrated in commercial and medical affairs functions, supporting a specialty ophthalmology product in peak phase competing against larger VEGF inhibitor franchises. The corticosteroid positioning requires targeted HCP engagement and differentiated value propositions to specialists treating VEGF-refractory or contraindicated patients.